Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 3 , ISSUE 1 ( January-June, 2013 ) > List of Articles

ORIGINAL ARTICLE

Ribavirin as a Therapeutic Modality in Patients with Severe Acute Hepatitis E

Salimur Rahman, Mamun Al-Mahtab, Faroque Ahmed, Md Fazal Karim, Md Dalil Uddin

Citation Information : Rahman S, Al-Mahtab M, Ahmed F, Fazal Karim M, Dalil Uddin M. Ribavirin as a Therapeutic Modality in Patients with Severe Acute Hepatitis E. Euroasian J Hepatogastroenterol 2013; 3 (1):39-41.

DOI: 10.5005/jp-journals-10018-1060

License: CC BY-NC 4.0

Published Online: 00-00-0000


Abstract

Background: With the postulation that ribavirin, an antiviral agent, can modulate the clinical course of severe acute hepatitis due to hepatitis E virus (HEV), a clinical trial was conducted in patients with acute hepatitis E. Materials and methods: A total of 24 patients with severe acute hepatitis E were enrolled in this study. Ribavirin was given at a dose of 400 mg, twice a day for 28 days. The clinical course of the disease was assessed on a regular basis. Results: Out of 24 patients in this cohort, three patients were lost during follow-up and their prognosis remains unknown. A total of six patients died during follow-up. The rest 15 patients showed improvement of their pathological conditions during observation period. Conclusion: Although preliminary, this study indicates that more information is required about beneficial and detrimental effects of ribavirin in patients with severe acute hepatitis E. This study inspired optimism that a randomized-controlled trial of ribavirin should be adopted in severe acute hepatitis E to develop proper in sights in this regard.


PDF Share
  1. Mast EE, Krawczynski K, Hepatitis E: An overview. Annu Rev Med 1996;47:257-66
  2. Hepatitis E: An emerging infection in developed countries. Lancet Infect Dis 2008;8:698-709
  3. Fulminant liver failure from acute autochthonous hepatitis E in France: Description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat 2007;14:298-303
  4. Hepatitis E superinfection produces severe decompensation in patients with chronic liver disease. J Gastroenterol Hepatol 2004;19:134-38
  5. Hepatitis E and pregnancy: Understanding the pathogenesis. Liver Int 2008;28: 1190-99
  6. Role of hepatitis E infection in acute on chronic liver failure in Egyptian patients. Liver Int 2011;31:1001-05
  7. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008;358:811-17
  8. Persistent carriage of hepatitis E virus in patients with HIV infection (Letter). N Engl J Med 2009;361:1025-27
  9. Treatment of severe acute hepatitis E by ribavirin. J Clin Virol 2011;52:60-62
  10. Brief communication: Case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med 2010;153:85-89
  11. Epidemiology and risk factors of incident hepatitis E virus infections in rural Bangladesh. Am J Epidemiol 2010;172:952-61. Ribavirin as a Therapeutic Modality in Patients with Severe Acute Hepatitis E Euroasian Journal of Hepato-Gastroenterology, January-June 2013;3(1):39-41 41 EJOHG 12. Mahtab MA, Rahman S, Khan M, Karim MF. Hepatitis E virus is a leading cause of acute-on-chronic liver disease: Experience from a tertiary centre in Bangladesh. Hepatobiliary Pancreat Dis Int 2009;8:50-52
  12. Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: A preliminary report. Antivir Ther 2012;17:1091-96.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.